Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Study Results Published Compare ABRAXANE(R) To Taxotere(R)
Abraxis BioScience Inc. (NASDAQ:ABII) announced that final results from an open-label Phase II study evaluating three dose levels of the company"s chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) compared to the highest standard dose of Taxotere (docetaxel) Injection Concentrate, in the first-line treatment of patients with metastatic breast cancer were published in the Journal of Clinical Oncology. According to investigator-assessed results, ABRAXANE administered weekly at 150 mg/m2 demonstrated an increase in progression-free survival (PFS) over docetaxel of 14.6 months versus 7.8 months, respectively (p=0.012). Results from the independent assessment of PFS for the 150mg/m2 treatment arm also demonstrated an increase in PFS (12.9 versus 7.5 months, respectively; p=0.0065). Investigators also noted a trend toward improvement in the study"s primary endpoint, overall response rate (ORR), confirmed complete and partial responses by Response Evaluation Criteria in Solid Tumors (RECIST) criteria with weekly ABRAXANE. In investigator-assessed results, the ORR was 74 percent for ABRAXANE 150 mg/m2 weekly arm (pAbout the Study
generic viagra online
WHO Antivirals Arrive In Nigeria
Tamiflu
News of the day
Merck KGaA Considers Appealing CHMP Opinion On Erbitux Treatment For Non-Small Cell Lung Cancer
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic non-small cell lung cancer (NSCLC). Merck KGaA is evaluating potential appeal options requesting that the CHMP re-examine data demonstrating clinical relevant benefits to patients.
Endocrinology

Abortion Issue Could Derail Health Reform

Nineteen Democrats have written House Speaker Nancy Pelosi promising not to vote for a health bill that includes funding for abortion, igniting a debate that has the potential to derail a health care overhaul, NPR reports. "I take a view that there"s almost anything [that can be compromised] in public affairs except probably the issue of abortion," said Sen. Charles Grassley (R-Iowa), one of the leading Republicans seeking a bipartisan health bill." "On Monday, the Senate Health, Education, Labor and Pensions Committee, the only one of five congressional committees overseeing the health effort that is actually drafting its bill, debated a half dozen abortion-related amendments. It defeated most on identical 12-11 votes, including one that would have barred people who get government insurance subsidies from buying private insurance plans that include abortion coverage. Sen. Tom Coburn (R-OK) said the principle is the same as the one that currently bans funding for abortion in the Medicaid program for the poor. "You are taking federal tax dollars and using them to provide abortion services," he said." "The committee"s debate was relatively brief, but the abortion issue hangs over the health overhaul effort like a dark, menacing cloud. Abortion foes, like Douglas Johnson of the National Right to Life Committee, say President Obama and congressional leaders plan to use the health care effort to dramatically increase the availability of abortion services." Others say most insurance plans cover abortion, contraception and women"s reproductive health and that such coverage will ensure women have the same access to care as men (Rovner, 7/14). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009